Clinical Usefulness of F-18 FDG PET/CT in Papillary Thyroid Cancer with Negative Radioiodine Scan and Elevated Thyroglobulin Level or Positive Anti-thyroglobulin Antibody

被引：23
作者：
Choi S.J. [1 ]
Jung K.P. [1 ]
Lee S.S. [1 ]
Park Y.S. [1 ]
Lee S.M. [1 ]
Bae S.K. [2 ]
机构：
[1] Department of Nuclear Medicine, Busan Paik Hospital, Inje University College of Medicine, 75 Bokji-ro, Busanjin-gu, Busan
[2] Department of Nuclear Medicine, Haeundae Paik Hospital, Inje University College of Medicine, 875 Haeun-daero, Haeundae-gu, Busan
来源：
Nuclear Medicine and Molecular Imaging | 2016年 / 50卷 / 2期
关键词：
FDG; Papillary thyroid cancer; PET/CT; Thyroglobulin; Thyroid stimulating hormone;
D O I：
10.1007/s13139-015-0378-5
中图分类号：
学科分类号：
摘要：
Purpose: Elevated thyroglobulin (Tg) levels, along with a negative radioiodine scan, present a clinical problem for the diagnosis of recurrence in papillary thyroid cancer (PTC) patients. The purpose of this study was to assess (1) the usefulness of 18F-fluorodeoxyglucose (F-18 FDG) positron emission tomography (PET)/computed tomography (CT) for PTC patients with negative diagnostic radioiodine scan and elevated serum Tg level or positive anti-thyroglobulin antibody (TgAb), and (2) the effect of endogenous thyroid stimulating hormone (TSH) stimulation (ETS) on detecting recurrence in these circumstances. Methods: Eighty-four patients with negative diagnostic radioiodine scan and elevated serum Tg or positive TgAb under ETS were included. Correlation with clinicopathological features and recurrence, detectability of FDG PET/CT and cut-off value of serum Tg for recurrence in PTC patients with these circumstance were assessed. In addition, detectability of F-18 FDG PET/CT under ETS and suppression were compared. Results: In Cox regression analysis, only serum Tg level was significantly associated with recurrence (P < 0.001, HR = 1.13; 95 % CI, 1.061–1.208). The cut-off level of Tg was 21.5 ng/mL (AUC, 0.919; P < 0.001) for discriminating the recurrence in the patients with positive PET/CT finding. The sensitivity, specificity, PPV, NPV, and accuracy of F-18 FDG PET/CT for detecting recurrence were 64 %, 94 %, 86 %, 81 %, and 83 %. In the analysis of F-18 FDG PET/CT under ETS, the sensitivity, specificity, PPV, NPV and accuracy was 64 %, 94 %, 88 %, 81 % and 83 %. Those under TSH suppression were 67 %, 92 %, 80 %, 85 % and 83 %. Conclusions: F-18 FDG PET/CT, although less sensitive, showed high specificity, PPV, NPV, and accuracy and therefore can be useful for the patients with negative diagnostic radioiodine scan and elevated serum Tg or positive TgAb. In addition, FDG PET/CT under ETS does not seem to have an additive role in detecting recurrence in these patients. © 2015, Korean Society of Nuclear Medicine.
引用
收藏
页码：130 / 136
页数：6
相关论文
共 27 条
  • [1] Jung K.W., Won Y.J., Kong H.J., Oh C.M., Seo H.G., Lee J.S., Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010, Cancer Res Treat, 45, pp. 1-14, (2013)
  • [2] Cooper D.S., Doherty G.M., Haugen B.R., Kloos R.T., Lee S.L., Mandel S.J., Et al., Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer, Thyroid, 19, pp. 1167-1214, (2009)
  • [3] Bertagna F., Bosio G., Biasiotto G., Rodella C., Puta E., Gabanelli S., Et al., F-18 FDG-PET/CT evaluation of patients with differentiated thyroid cancer with negative I-131 total body scan and high thyroglobulin level, Clin Nucl Med, 34, pp. 756-761, (2009)
  • [4] Smooke-Paw S., Ro K., Levin O., Ituarte P.H., Harari A., Yeh M.W., Thyroglobulin antibody levels do not predict disease status in papillary thyroid cancer, Clin Endocrinol, 81, pp. 271-275, (2014)
  • [5] Schluter B., Bohuslavizki K.H., Beyer W., Plotkin M., Buchert R., Clausen M., Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative I-131 Scan, J Nucl Med, 42, pp. 71-76, (2001)
  • [6] Lubin E., Mechlis-Frish S., Zatz S., Shimoni A., Segal K., Avraham A., Et al., Serum thyroglobulin and iodine-131 whole-body scan in the diagnosis and assessment of treatment for metastatic differentiated thyroid carcinoma, J Nucl Med, 35, pp. 257-262, (1994)
  • [7] Abraham T., Schoder H., Thyroid cancer--indications and opportunities for positron emission tomography/computed tomography imaging, Semin Nucl Med, 41, pp. 121-138, (2011)
  • [8] Ozkan E., Aras G., Kucuk N.O., Correlation of F-18 FDG PET/CT findings with histopathological results in differentiated thyroid cancer patients who have increased thyroglobulin or antithyroglobulin antibody levels and negative I-131 whole-body scan results, Clin Nucl Med, 38, pp. 326-331, (2013)
  • [9] Seo J.H., Lee S.W., Ahn B.C., Lee J., Recurrence detection in differentiated thyroid cancer patients with elevated serum level of antithyroglobulin antibody: special emphasis on using <sup>18</sup>F-FDG PET/CT, Clin Endocrinol, 72, pp. 558-563, (2010)
  • [10] Ozkan E., Soydal C., Araz M., Aras G., Ibis E., The additive clinical value of F-18 FDG PET/CT in defining the recurrence of disease in patients with differentiated thyroid cancer who have isolated increased antithyroglobulin antibody levels, Clin Nucl Med, 37, pp. 755-758, (2012)
123